Bioprist regulates it Central American Operations from its head office based in Houston-Texas, USA.
From its base in Montego bay-Jamaica, Bioprist Pharmaceuticals regulates its wider Caribbean Operations catering to the Cayman Islands, Bahamas, Turks & Caicos Islands, Haiti, Dominican Republic, Eastern Caribbean Islands, Trinidad & Tobago and Guyana.
Bioprist drug formulation brands are currently marketed and distributed in Jamaica by its own independent subsidiary "Indies Pharma Jamaica Limited".
In support of its wider Caribbean operations Bioprist has acquired in the early part of 2011 a sizable factory / warehousing property complex across from the shipping terminal on the wharf in Free Port, Montego Bay-Jamaica. It aims to establish by 2013 its state of the art multimillion dollar warehousing terminal to support its future regional logistics.
Bioprist's major strength today is its extremely invaluable insight into the local markets, solid human resources as field force infrastructure (Medical & Product Sales Representatives), impeccable intellectual property attested by almost 200 trade marks owned by its founders in this region.
Currently, almost 400 dossiers were filed in the region while another 200 are in the process of filing between 2012 and 2013.
Bioprist is poised to grow as the single largest house for branded generic drug formulations in this region by 2015 while it is also in the active process of appointing distributors in each country for its brands supported by strategic employment of its own marketing team in the respective countries of the region.
Bioprist understood the power of the FMCG – Fast Moving Consumer Brands and decided to open its door for a new division "Bioprist Consumer Health Care Division" to enter into the consumer brand market in the United States, Latin America, the wider Caribbean and across the Globe.
Learn how combining sugar and protein affect the quality of the body's absorption of protein.